Cite
SHORT REPORT Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma.
MLA
Thompson, Michael A., et al. “SHORT REPORT Plasma Levels of Tumour Necrosis Factor Alpha and Interleukin-6 Predict Progression-Free Survival Following Thalidomide Therapy in Patients with Previously Untreated Multiple Myeloma.” British Journal of Haematology, vol. 123, no. 2, Oct. 2003, p. 305. EBSCOhost, https://doi.org/10.1046/j.1365-2141.2003.04605.x.
APA
Thompson, M. A., Witzig, T. E., Kumar, S., Timm, M. M., Haug, J., Fonseca, R., Greipp, P. R., Lust, J. A., & Rajkumar, S. V. (2003). SHORT REPORT Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. British Journal of Haematology, 123(2), 305. https://doi.org/10.1046/j.1365-2141.2003.04605.x
Chicago
Thompson, Michael A., Thomas E. Witzig, Shaji Kumar, Michael M. Timm, Jessica Haug, Rafael Fonseca, Philip R. Greipp, John A. Lust, and S. Vincent Rajkumar. 2003. “SHORT REPORT Plasma Levels of Tumour Necrosis Factor Alpha and Interleukin-6 Predict Progression-Free Survival Following Thalidomide Therapy in Patients with Previously Untreated Multiple Myeloma.” British Journal of Haematology 123 (2): 305. doi:10.1046/j.1365-2141.2003.04605.x.